WO2003027671A3 - Apoptosis - Google Patents

Apoptosis Download PDF

Info

Publication number
WO2003027671A3
WO2003027671A3 PCT/GB2002/004343 GB0204343W WO03027671A3 WO 2003027671 A3 WO2003027671 A3 WO 2003027671A3 GB 0204343 W GB0204343 W GB 0204343W WO 03027671 A3 WO03027671 A3 WO 03027671A3
Authority
WO
WIPO (PCT)
Prior art keywords
apoptosis
modulation
identification
disclosed
mtor
Prior art date
Application number
PCT/GB2002/004343
Other languages
French (fr)
Other versions
WO2003027671A2 (en
Inventor
Ian Hayes
Guido Kroemer
Karine Ferri
Maria Castedo
Original Assignee
Eirx Therapeutics Ltd
Inst Gustave Roussy L
Centre Nat Rech Scient
Ian Hayes
Guido Kroemer
Karine Ferri
Maria Castedo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eirx Therapeutics Ltd, Inst Gustave Roussy L, Centre Nat Rech Scient, Ian Hayes, Guido Kroemer, Karine Ferri, Maria Castedo filed Critical Eirx Therapeutics Ltd
Publication of WO2003027671A2 publication Critical patent/WO2003027671A2/en
Publication of WO2003027671A3 publication Critical patent/WO2003027671A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1758—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11001—Non-specific serine/threonine protein kinase (2.7.11.1), i.e. casein kinase or checkpoint kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Abstract

The present invention relates to the modulation of apoptosis, in particular it relates to the use of mTOR in the modulation of syncitial apoptosis. A method for the identification of further molecules involved in apoptosis, and the use mTOR in the treatment of disease are also disclosed. In addition, assays associated with the identification of such molecules are disclosed.
PCT/GB2002/004343 2001-09-25 2002-09-25 Apoptosis WO2003027671A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0123025A GB0123025D0 (en) 2001-09-25 2001-09-25 Apoptosis
GB0123025.9 2001-09-25

Publications (2)

Publication Number Publication Date
WO2003027671A2 WO2003027671A2 (en) 2003-04-03
WO2003027671A3 true WO2003027671A3 (en) 2004-03-11

Family

ID=9922637

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/004343 WO2003027671A2 (en) 2001-09-25 2002-09-25 Apoptosis

Country Status (2)

Country Link
GB (1) GB0123025D0 (en)
WO (1) WO2003027671A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1627048A4 (en) 2003-05-16 2008-10-15 Univ Maryland Biotech Inst Compositions for down-regulation of ccr5 expression and methods of use therefor
GB0327840D0 (en) * 2003-12-01 2003-12-31 Novartis Ag Organic compounds
CN109122581A (en) * 2018-09-18 2019-01-04 南通市第二人民医院 Fra-1 and application of the XPA compound in cell cycle regulating

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041865A1 (en) * 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamcycin-based regulation of biological events

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996041865A1 (en) * 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamcycin-based regulation of biological events

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CASTEDO MARIA ET AL: "Human immunodeficiency virus 1 envelope glycoprotein complex-induced apoptosis involves mammalian target of rapamycin/FKBP12-rapamycin-ass ociated protein-mediated p53 phosphorylation.", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 194, no. 8, 15 October 2001 (2001-10-15), pages 1097 - 1110, XP001154438, ISSN: 0022-1007 *
CASTEDO MARIA ET AL: "Sequential involvement of Cdk1, mTOR and p53 in apoptosis induced by the HIV-1 envelope.", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 21, no. 15, 1 August 2002 (2002-08-01), August 1, 2002, pages 4070 - 4080, XP001154440, ISSN: 0261-4189 *
HOSOI HAJIME ET AL: "Rapamycin causes poorly reversible inhibition of mTOR and induces p53-independent apoptosis in human rhabdomyosarcoma cells.", CANCER RESEARCH, vol. 59, no. 4, 15 February 1999 (1999-02-15), pages 886 - 894, XP001154916, ISSN: 0008-5472 *
HUANG S ET AL: "MECHANISMS OF RESISTANCE TO RAPAMYCINS", DRUG RESISTANCE UPDATES, CHURCHILL LIVINGSTONE, EDINBURGH, GB, vol. 4, no. 6, December 2001 (2001-12-01), pages 378 - 391, XP001094520, ISSN: 1368-7646 *
YAROSH DANIEL B ET AL: "FRAP DNA-dependent protein kinase mediates a late signal transduced from ultraviolet-induced DNA damage.", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 114, no. 5, May 2000 (2000-05-01), pages 1005 - 1010, XP001154555, ISSN: 0022-202X *

Also Published As

Publication number Publication date
GB0123025D0 (en) 2001-11-14
WO2003027671A2 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
WO2004074455A3 (en) Fc REGION VARIANTS
EP1765388B8 (en) Combination therapy for preventing or treating alzheimer's disease, and kit therefor
WO2007149481A3 (en) Tetrahydro-isoalpha acid based protein kinase modulation cancer treatment
WO2004050707A3 (en) Tumor-specific recognition molecules
WO2006127757A3 (en) Interferon-igg fusion
MXPA03007983A (en) Process for the preparation of middle distillates.
WO2004007743A3 (en) Use of cpg nucleic acids in prion-disease
MXPA03007197A (en) Therapeutic binding molecules.
WO2006019982A3 (en) Pin1-modulating compounds and methods of use thereof
ZA200204312B (en) Laminate and process for its manufacture.
WO2006110588A8 (en) Methods for treating mild cognitive impairment
WO2007028151A3 (en) Surgical devices and related methods thereof
WO2003066821A3 (en) Molecules interacting with casl (mical) polynucleotides, polypeptides, and methods of using the same
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
AU2002309083A1 (en) Method for identifying drugs for the treatment of type ii diabetes
WO2005010165A3 (en) Non-glycosylated human alpha-fetoprotein, methods of production, and uses thereof
AU2003215190A1 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
AU2002329784A1 (en) Molecules for disease detection and treatment
WO2003027671A3 (en) Apoptosis
WO2002061430A3 (en) Methods and reagents for treating autoimmune disorders
WO2003017817A3 (en) Diagnosis, prevention and treatment of cancer
WO2004078142A3 (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions
BR0200047B1 (en) dioximethylene derivatives, process for producing compound based on dioximethylene derivatives, and method for enhancing, enhancing or modifying the odor properties of a fragrance.
WO2005017177A3 (en) Modulators of nod1 signaling
CA97627S (en) Door opener lever

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP